8-K/A: Mirum Pharmaceuticals Completes Bluejay Therapeutics Acquisition

Mirum Pharmaceuticals has amended its Form 8-K to include financial statements and pro forma information following its acquisition of Bluejay Therapeutics and a concurrent private placement.

Summary

• Mirum Pharmaceuticals, Inc. (the Company) has filed an amendment to its Form 8-K to include historical financial statements for Bluejay Therapeutics, Inc. and pro forma financial information related to the acquisition of Bluejay and a subsequent private placement.
• The acquisition of Bluejay Therapeutics was completed on January 23, 2026, following a merger agreement dated December 6, 2025.
• Immediately after the acquisition, Mirum completed a private placement, raising approximately $268.5 million in gross proceeds by issuing 3,385,149 shares of common stock and pre-funded warrants.
• The historical audited financial statements of Bluejay Therapeutics for the year ended December 31, 2025, are included as Exhibit 99.1.
• Unaudited pro forma condensed combined financial information, reflecting the acquisition and private placement, is included as Exhibit 99.2.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, reflecting the successful completion of a significant acquisition and capital raise, but also acknowledging the inherent risks and financial losses associated with biopharmaceutical development.

Positives

• Successful completion of the acquisition of Bluejay Therapeutics, a clinical-stage biopharmaceutical company.
• Successful completion of a private placement raising approximately $268.5 million in gross proceeds.
• Addition of Bluejay's lead product candidate, brelovitug, for chronic hepatitis delta, to Mirum's pipeline.

Negatives

• Bluejay Therapeutics incurred significant net losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern prior to the acquisition.
• The pro forma combined entity is expected to continue to incur losses, with no tax benefits recognized due to full valuation allowances on deferred tax assets.
• The acquisition is accounted for as an asset acquisition, with the majority of the purchase price allocated to in-process research and development (IPR&D), which is immediately expensed.

Risks

• Bluejay Therapeutics' lead product candidate, brelovitug, is in clinical development, and there is no assurance of successful completion of clinical trials or regulatory approval.
• The Company faces uncertainties related to the projections of patient populations for targeted diseases.
• The Company's ability to obtain, maintain, and protect its intellectual property rights is critical.
• The Company is subject to risks associated with clinical drug development, including demonstrating safety and efficacy, and enrolling patients in trials.
• The Company's future results are subject to general economic and market conditions.

Future Outlook

The pro forma combined entity is expected to continue to incur significant losses due to ongoing research and development activities. No tax benefits are expected to be realized due to full valuation allowances on deferred tax assets.

Management Comments

• The Company is filing this amendment to the Original 8-K to amend and supplement the Original 8-K to include historical financial statements of Bluejay and pro forma financial information as required by Items 9.01(a) and 9.01(b), respectively, of Form 8-K and that were excluded from the Original 8-K in reliance on the instructions to such items.
• The unaudited pro forma condensed combined financial information has been prepared to illustrate the estimated effects of the Acquisition and the PIPE.

Industry Context

StockSavvy.ai notes that this filing details a significant strategic move by Mirum Pharmaceuticals to acquire Bluejay Therapeutics, bolstering its pipeline in the competitive biopharmaceutical sector, particularly in the area of viral and liver diseases. The concurrent private placement indicates investor confidence in the combined entity's future potential, despite the inherent risks in drug development.

Comparison to Industry Standards

• The acquisition of Bluejay Therapeutics by Mirum Pharmaceuticals aligns with industry trends of consolidation in the biopharmaceutical sector, where companies seek to acquire promising clinical-stage assets to accelerate growth and expand their portfolios.
• The accounting treatment of the acquisition as an asset acquisition with a significant portion of the purchase price allocated to IPR&D is common in the industry when the acquired entity's primary value lies in its development pipeline.
• The private placement of $268.5 million is a substantial amount, reflecting the current market appetite for well-positioned biopharmaceutical companies, though the valuation metrics used for the PIPE shares ($68.48 per share) would need to be compared against industry benchmarks for similar-stage companies at the time of the transaction.

Stakeholder Impact

• Shareholders of Mirum Pharmaceuticals now have an interest in Bluejay's pipeline and assets, alongside the risks and potential rewards of the combined entity.
• Bluejay Therapeutics' former security holders have received Mirum Pharmaceuticals' common stock and/or cash as consideration for the acquisition.
• Employees of both Mirum and Bluejay will be subject to the combined company's operational structure and policies.

Next Steps

• Mirum Pharmaceuticals will continue to develop Bluejay's lead product candidate, brelovitug.
• The company will integrate Bluejay's operations and pipeline into its existing structure.
• Further financial reporting will reflect the combined entity's performance.

Key Dates

Recommendation

The filing details a significant acquisition and a substantial capital raise, which are positive developments. However, the inherent risks in biopharmaceutical development, the accounting treatment of the acquisition as an asset purchase with immediate expensing of IPR&D, and the continued expected losses for the combined entity warrant a cautious 'hold' recommendation until further clinical and commercial progress is demonstrated.

Keywords

Mirum Pharmaceuticals, Bluejay Therapeutics, Acquisition, Merger, Private Placement, Form 8-K/A, Biopharmaceutical, Hepatitis Delta